Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the closing of its underwritten public offering of 41,071,428 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase 5,357,142 additional shares of its common stock, at a public offering price of $3.50 per share. All of the shares of common stock in the offering were sold by Prime Medicine. The gross proceeds to Prime Medicine from the offering, before deducting underwriting discounts and commissions and offering expenses, were approximately $143.7 million.

Jefferies, TD Cowen and Goldman Sachs & Co. LLC acted as joint book-running managers for the offering. Oppenheimer & Co. and LifeSci Capital acted as passive book-running managers for the offering.